OCT Angiography Findings in Preclinical Alzheimer’s Disease: 3-Year Follow-Up

Preclinical Alzheimer’s disease (AD) is a recognized disease stage in which amyloid begins to accumulate within the central nervous system before the onset of disease symptoms. Preclinical AD is diagnosed by measuring amyloid burden either by neuroimaging with amyloid markers or by direct measurement within cerebrospinal fluid (CSF). 1 Roe C.M. Fagan A.M. Grant E.A. et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013; 80: 1784-1791 Crossref PubMed Scopus (164) Google Scholar However, these methods are time-consuming and invasive. Our prior study demonstrated alterations in the foveal avascular zone (FAZ) of eyes from subjects with preclinical AD compared with eyes from age-matched controls. 2 O’Bryhim B.E. Apte R.S. Kung N. et al. Association of preclinical Alzheimer disease with optical coherence tomographic angiography findings. JAMA Ophthalmol. 2018; 136: 1242-1248 Crossref PubMed Scopus (119) Google Scholar We present the first longitudinal follow-up of these study subjects at 3 years.